Sandostatin

Diagnosing
Carcinoid Syndrome

Carcinoid tumors are difficult to diagnose. They can be active or inactive. Sometimes a carcinoid tumor will actively release hormones into the body resulting in symptoms. If the carcinoid tumors are inactive, they may not produce any symptoms at all, making them difficult to detect.1

Doctors rely on different methods to diagnose and monitor carcinoid syndrome. One test is called a 5-hydroxyindoleacetic acid (5-HIAA) test because it tests for the presence of 5-HIAA, a metabolite of serotonin, the hormone that causes symptoms of carcinoid syndrome. The simple test measures the amount of 5-HIAA in your urine. This test is very helpful because most patients with carcinoid syndrome overproduce serotonin and its metabolite, 5-HIAA.2,3

Read more about the diagnosis and management of carcinoid syndrome.

INDICATIONS AND USAGE

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is a prescription medicine indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

  • Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal).
  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Before taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects you may experience include:

  • Acromegaly: diarrhea, gallstones, abdominal pain, and flatulence
  • Carcinoid tumors: back pain, fatigue, headache, abdominal pain, nausea, and dizziness

Other information: Patients with carcinoids tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

(1) Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-1289.

(2) Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1559-1574.

(3) McCormick D. Carcinoid tumors and syndrome. Gastroenterol Nurs. 2002;25:105-111.

Important Safety Information

 

Walk 3 cities — virtually

Learn about
carcinoid syndrome

Earn money for
patient groups

Take the first step now!
FOR CARCINOID SYNDROME
Sandostatin® CONTROL
Enroll today, and get a
Personalized Doctor
Discussion Guide,

along with useful
information on the
severe diarrhea and
flushing associated
with carcinoid
syndrome.
ENROLL NOW